Loviride (BioDeep_00000180545)

   

human metabolite blood metabolite


代谢物信息卡片


2-[(2-acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide

化学式: C17H16Cl2N2O2 (350.0589)
中文名称: 洛韦胺
谱图信息: 最多检出来源 Homo sapiens(blood) 96.95%

分子结构信息

SMILES: CC(=O)C1=C(NC(C(N)=O)C2=C(Cl)C=CC=C2Cl)C=C(C)C=C1
InChI: InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)

描述信息

C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent

同义名列表

2 个代谢物同义名

2-[(2-acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide; Loviride



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Lakshmi N Ramana, Swaminathan Sethuraman, Udaykumar Ranga, Uma M Krishnan. Development of a liposomal nanodelivery system for nevirapine. Journal of biomedical science. 2010 Jul; 17(?):57. doi: 10.1186/1423-0127-17-57. [PMID: 20624325]
  • Ennio Polilli, Giustino Parruti, Luana Cosentino, Federica Sozio, Annalisa Saracino, Augusta Consorte, Gioacchino Angarano, Francesco Di Masi, Elena Mazzotta, Paolo Fazii. Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. Journal of medical case reports. 2009 Sep; 3(?):9132. doi: 10.4076/1752-1947-3-9132. [PMID: 21092074]
  • NULL. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antiviral therapy. 2002 Mar; 7(1):11-20. doi: NULL. [PMID: 12008783]
  • J R Clarke, S Kaye, A G Babiker, M H Hooker, R Tedder, J N Weber. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. Journal of virological methods. 2000 Aug; 88(2):117-24. doi: 10.1016/s0166-0934(00)00173-7. [PMID: 10960699]
  • J Gatell, J Lange, M Gartland. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group. Antiviral therapy. 1999; 4(2):79-86. doi: NULL. [PMID: 10682152]
  • J S Montaner, R DeMasi, A M Hill. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS (London, England). 1998 Mar; 12(5):F23-8. doi: 10.1097/00002030-199805000-00003. [PMID: 9543436]
  • S Staszewski, V Miller, S Rehmet, T Stark, J De Crée, M De Brabander, M Peeters, K Andries, M Moeremans, M De Raeymaeker, G Pearce, R Van den Broeck, W Verbiest, P Stoffels. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS (London, England). 1996 May; 10(5):F1-7. doi: 10.1097/00002030-199605000-00001. [PMID: 8724034]